Abbott's TriClip G4 tricuspid valve repair system obtains EU CE certification

CompilationFan Dongdong

A few days ago, Abbott's latest generation of upgraded minimally invasive transcatheter tricuspid valve repair system TriClip G4 has obtained CE mark approval from European regulatory agencies to help prevent blood leakage from the patient's heart tricuspid valve.

In April 2020, Abbott’s first transcatheter tricuspid valve repair system, TriClip, obtained the European CE mark certification and was approved for sale in the European market and other countries and regions that recognized the European CE mark.

Compared with the left mitral valve of the heart, the tricuspid valve separates the right atrium and ventricle of the heart, and at the same time is responsible for the function of pushing blood to the lungs to absorb new oxygen.

The TriClip system is developed on the basis of the company's other best-selling cardiac repair device MitraClip.

The TriClip system uses the same clamping technology as the MitraClip system.

Previously, Abbott conducted a TRILUMINATE trial to evaluate the safety and effectiveness of TriClip in reducing tricuspid regurgitation in 21 medical centers in Europe and the United States.

In addition, TriClip has recently been approved in Canada, but the device has not yet received regulatory approval in the United States.

Reference source:

1.

2.